Edition:
India

RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger With Idera Pharmaceuticals


Monday, 2 Apr 2018 

April 2 (Reuters) - Idera Pharmaceuticals Inc ::RA CAPITAL MANAGEMENT OPPOSES BIOCRYST PHARMACEUTICALS' PROPOSED MERGER WITH IDERA PHARMACEUTICALS.‍RA CAPITAL MANAGEMENT SAYS HAS BENEFICIAL OWNERSHIP OF ABOUT 7.1 PERCENT OF BIOCRYST PHARMACEUTICALS' COMMON STOCK​.RA CAPITAL SAYS HAS "SERIOUS CONCERNS" ABOUT BIOCRYST PHARMACEUTICALS' PROPOSED DEAL WITH IDERA AND ITS "DILUTIVE IMPACT" ON BIOCRYST SHAREHOLDERS ‍​. 

Company Quote

2.91
 --
17 Sep 2019